Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791922 | 0.83 | ALDH1A1 (0.40) | — | |
| SCHEMBL26241674 | 0.81 | XIAP (0.38) | GRM2 | |
| SCHEMBL23791809 | 0.79 | NOTUM (0.43) | — | |
| SCHEMBL23782523 | 0.75 | ADORA2A (0.40) | — | |
| SCHEMBL30173753 | 0.75 | ADORA2A (0.40) | — | |
| SCHEMBL6909946 | 0.74 | HTR2A (0.39) | — | |
| SCHEMBL23791840 | 0.69 | KDM5B (0.40) | — | |
| SCHEMBL19626496 | 0.69 | ALDH1A1 (0.40) | — | |
| SCHEMBL30173814 | 0.69 | FBP1 (0.44) | — | |
| SCHEMBL23782557 | 0.69 | FBP1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | GRM2 3571/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | GRM2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.